Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers (U54)

Post Date

May 13th 2009

Application Due Date

November 10th 2009

Funding Opportunity Number

RFA-HD-09-027

CFDA Number(s)

93.837
93.846
93.853
93.865

Funding Instrument Type(s)

Cooperative Agreement

Funding Activity Categories

Health
Income Security and Social Services

Number of Awards

3

Eligibility Categories

Public and State Controlled Institutions of Higher Education
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs).

Funding

• Estimated Total Funding:

  $3000000

• Award Range:

  $None - $1000000

Grant Description

Purpose. This funding opportunity announcement (FOA) solicits new (type 1) and competitive renewal (type 2) applications for the support of Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers (MDCRCs). Successful applicants will join a network of existing Centers to foster the translation of new scientific findings and technological developments into novel treatments for the muscular dystrophies. Each Center may contain a mixture of basic, translational, or clinical research, as long as efforts are directed toward the steps required for therapeutic development, including therapeutic target identification, characterization, and validation, development of diagnostics and biomarkers to characterize or stratify patient populations, in vitro assay development, animal model development and characterization, candidate therapeutic efficacy screening, preclinical therapeutic optimization and FDA-required activities leading to an investigational new drug (IND) application, clinical infrastructure and studies in support of a clinical trial, patient-oriented natural history studies, and early stage clinical trials for one or more types of muscular dystrophy. Applicants should propose multi-disciplinary and collaborative studies that address one or more gaps in the therapeutic development pipeline for muscular dystrophy. Research problems should require substantial collaborative efforts to solve, and thus are best carried out in a center setting. Mechanism of Support. This FOA will utilize the U54 Specialized Centers Cooperative Agreement grant mechanism.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-09-027.html